Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 05 2020
08 05 2020
Historique:
received:
26
02
2020
accepted:
21
04
2020
entrez:
10
5
2020
pubmed:
10
5
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treatment of osteoporosis and metastasis. In this study, graphene oxide (GO) is conjugated with ZOL, and the nanostructured material is evaluated in terms viability, proliferation and differentiation. Furthermore, the associated morphological changes of bone marrow-derived mesenchymal stem cells (BM-MSC), and Michigan Cancer Foundation-7 (MCF-7) breast cancer cells, as well as the effect of the drugs on mineralization of BM-MSCs are investigated using a variety of characterization techniques including Fourier Transform Infrared Spectroscopy (FTIR), scanning electron microscopy (SEM) as well as alamar blue, acridine orange, and alizarin red assays. Nanostructured ZOL-GO with an optimum performance is synthesized using ZOL and GO suspensions with the concentration of 50 µM and 2.91 ng/ml, respectively. ZOL-GO nanostructures can facilitate the mineralization of BM-MSC cells, demonstrated by the formation of clusters around the cells. The results obtained confirm the performance of ZOL-GO nanostructures as promising drug complexes for the treatment of osteoporosis and metastasis.
Identifiants
pubmed: 32385391
doi: 10.1038/s41598-020-64760-4
pii: 10.1038/s41598-020-64760-4
pmc: PMC7211009
doi:
Substances chimiques
graphene oxide
0
Zoledronic Acid
6XC1PAD3KF
Graphite
7782-42-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7827Références
Schmid-Alliana, A. et al. Understanding the progression of bone metastases to identify novel therapeutic targets. Int. J. Mol. Sci. 19, 148–168 (2018).
pmcid: 5796097
doi: 10.3390/ijms19010148
Macedo, F. et al. Bone metastases: An overview. Oncol. Rev. 11, 43–49 (2017).
doi: 10.4081/oncol.2017.321
Svensson, E., Christiansen, C. F., Ulrichsen, S. P., Rørth, M. R. & Sørensen, H. T. Survival after bone metastasis by primary cancer type: A Danish population-based cohort study. BMJ Open 7, 1–7 (2017).
doi: 10.1136/bmjopen-2017-016022
Fournier, P. G., Stresing, V., Ebetino, F. H. & Clézardin, P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 12, 571–8 (2010).
pubmed: 20651986
pmcid: 2907583
doi: 10.1593/neo.10282
Junankar, S. & Rogers, M. J. In Bone Cancer 615–627 (Elsevier, 2015).
Nadar, R. A. et al. Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer. Adv. Healthc. Mater. 6, 1601119–1601137 (2017).
doi: 10.1002/adhm.201601119
Polascik, T. J. Bisphosphonates in oncology: Evidence for the prevention of skeletal events in patients with bone metastases. Drug Des. Devel. Ther. 3, 27–40 (2009).
pubmed: 19920919
pmcid: 2769231
Torger, B. et al. Cast adhesive polyelectrolyte complex particle films of unmodified or maltose-modified poly (ethyleneimine) and cellulose sulphate: Fabrication, film stability and retarded release of zoledronate. Biointerphases 8, 1–11 (2013).
doi: 10.1186/1559-4106-8-25
Jagdev, S. P., Coleman, R. E., Shipman, C. M., Rostami-H, A. & Croucher, P. I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br. J. Cancer 84, 1126–1134 (2001).
pubmed: 11308265
pmcid: 2363858
doi: 10.1054/bjoc.2001.1727
Kellinsalmi, M. et al. In vitro Comparison of Clodronate, Pamidronate and Zoledronic Acid Effects on Rat Osteoclasts and Human Stem Cell-Derived Osteoblasts. J. Pharmacol. Toxicol. 97, 382–391 (2005).
Patntirapong, S., Singhatanadgit, W. & Chanruangvanit, C. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition. J. Oral Pathol. Med. 41, 713–720 (2012).
pubmed: 22563819
doi: 10.1111/j.1600-0714.2012.01154.x
Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18, 75–85 (1996).
pubmed: 8833200
doi: 10.1016/8756-3282(95)00445-9
Göbel, A. et al. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Lett. 375, 162–171 (2016).
pubmed: 26968247
doi: 10.1016/j.canlet.2016.03.004
Tanvetyanon, T. & Stiff, P. J. Management of the adverse effects associated with intravenous bisphosphonates. An. Oncol. 17, 897–907 (2006).
doi: 10.1093/annonc/mdj105
Shane, E., Khosla, S. & Burr, D. in Osteoporosis 1873–1883 (Academic Press, 2013).
Khajuria, D. K., Vasireddi, R., Trebbin, M., Karasik, D. & Razdan, R. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation. Mater. Sci. Eng. C 71, 698–708 (2017).
doi: 10.1016/j.msec.2016.10.066
Gou, W. et al. Controlled delivery of zoledronate improved bone formation locally In Vivo. PLoS One 9, 1–9 (2014).
Shmeeda, H. et al. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J. Control. Release 146, 76–83 (2010).
pubmed: 20462513
doi: 10.1016/j.jconrel.2010.04.028
Kadow-Romacker, A., Greiner, S., Schmidmaier, G. & Wildemann, B. Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro. J. Biomater. Appl. 27, 577–585 (2013).
pubmed: 21862509
doi: 10.1177/0885328211415722
Raina, D. B. et al. A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone. Sci. Rep. 6, 1–13 (2016).
doi: 10.1038/srep26033
Raina, D. B. et al. Gelatin- hydroxyapatite- calcium sulphate based biomaterial for long term sustained delivery of bone morphogenic protein-2 and zoledronic acid for increased bone formation: In-vitro and in-vivo carrier properties. J. Control. Release 272, 83–96 (2018).
pubmed: 29329716
doi: 10.1016/j.jconrel.2018.01.006
Liu, Z., Robinson, J. T., Tabakman, S. M., Yang, K. & Dai, H. Carbon materials for drug delivery & cancer therapy. Mater. Today 14, 316–323 (2011).
doi: 10.1016/S1369-7021(11)70161-4
Lim, D. J., Sim, M., Oh, L., Lim, K. & Park, H. Carbon-based drug delivery carriers for cancer therapy. Arch. Pharm. Res. 37, 43–52 (2014).
pubmed: 24234911
doi: 10.1007/s12272-013-0277-1
Banks, C. E., Crossley, A., Salter, C., Wilkins, S. J. & Compton, R. G. Carbon nanotubes contain metal impurities which are responsible for the ‘electrocatalysis’ seen at some nanotube-modified electrodes. Angew. Chemie - Int. Ed. 45, 2533–2537 (2006).
doi: 10.1002/anie.200600033
Zhang, R. & Olin, H. Carbon nanomaterials as drug carriers: Real time drug release investigation. Mater. Sci. Eng. C 32, 1247–1252 (2012).
doi: 10.1016/j.msec.2012.03.016
Sahoo, N. G. et al. Functionalized carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: A comparative study. Chem. Commun. 47, 5235–5237 (2011).
doi: 10.1039/c1cc00075f
Pan, Y., Sahoo, N. G. & Li, L. The application of graphene oxide in drug delivery. Expert Opin. Drug Deliv. 9, 1365–1376 (2012).
pubmed: 23005029
doi: 10.1517/17425247.2012.729575
Ege, D., Kamali, A. R. & Boccaccini, A. R. Graphene Oxide/Polymer-Based Biomaterials. Adv. Eng. Mater. 1700627, 16–34 (2017).
Yang, X. et al. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J. Phys. Chem. C 112, 17554–17558 (2008).
doi: 10.1021/jp806751k
Wu, J. et al. Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells. Nanotechnology 23, 1–9 (2012).
Hussien, N. A., Işıklan, N. & Türk, M. Pectin-conjugated magnetic graphene oxide nanohybrid as a novel drug carrier for paclitaxel delivery. Artif. Cells, Nanomedicine Biotechnol. 46, 264–273 (2018).
doi: 10.1080/21691401.2017.1421211
Yang, L. et al. Functionalized graphene oxide as a drug carrier for loading pirfenidone in treatment of subarachnoid hemorrhage. Colloids Surfaces B Biointerfaces 129, 21–29 (2015).
pubmed: 25819362
doi: 10.1016/j.colsurfb.2015.03.022
Gautam, S. Graphene Oxide: A Potential Drug Carrier for Cancer Therapy — Review. Res. Rev. A J. Pharm. Sci. 8, 20–31 (2018).
Tiwari, G. et al. Drug delivery systems_ An updated review. Int J Pharm Investig. 2, 2–11 (2012).
pubmed: 23071954
pmcid: 3465154
doi: 10.4103/2230-973X.96920
Zhang, X., Hu, W., Li, J., Tao, L. & Wei, Y. A comparative study of cellular uptake and cytotoxicity of multi-walled carbon nanotubes, graphene oxide, and nanodiamond. Toxicol. Res. (Camb). 1, 62–68 (2012).
doi: 10.1039/c2tx20006f
Manoratne, C. H., Rosa, S. R. D. & Kottegoda, I. R. M. XRD-HTA, UV Visible, FTIR and SEM Interpretation of Reduced Graphene Oxide Synthesized from High Purity Vein Graphite. Mater. Sci. Res. India 14, 19–30 (2017).
doi: 10.13005/msri/140104
Parades, J. I., Villar-Rodil, S., Martínez-Alonso, A. & Tascón, J. M. D. Graphene oxide dispersions in organic solvents. Langmuir 24, 10560–10564 (2008).
doi: 10.1021/la801744a
He, D. et al. Mechanism of a green graphene oxide reduction with reusable potassium carbonate. RSC Adv. 5, 11966–11972 (2015).
doi: 10.1039/C4RA14511A
Çiplak, Z., Yildiz, N. & Cąlimli, A. Investigation of graphene/Ag nanocomposites synthesis parameters for two different synthesis methods. Fullerenes Nanotub. Carbon Nanostructures 23, 361–370 (2015).
doi: 10.1080/1536383X.2014.894025
Khajuria, D. K., Razdan, R. & Mahapatra, D. R. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model. Eur. J. Pharm. Sci. 66, 173–183 (2015).
pubmed: 25444840
doi: 10.1016/j.ejps.2014.10.015
Prasanthi, M. M., Rao, B. A., Rao, B. V. N., Krishna, Y. P. & Ramana, D. V. Formulation and Evaluation of Zoledronic Acid for Injection By Lyophilization Technique. Int. Res. J. Pharm. 8, 50–56 (2017).
Chen, S., Wan, P., Zhang, B., Yang, K. & Li, Y. Facile fabrication of the zoledronate-incorporated coating on magnesium alloy for orthopaedic implants. J. Orthop. Transl. (2019).
Tavakoli, S. & Ege, D. Graphene Oxide as a drug carrier for delivery of zoledronic acid in secondary bone cancer treatment. MRS Adv. 4, 1231–1235 (2019).
doi: 10.1557/adv.2019.117
Ural, A. U., Avcu, F., Candir, M., Guden, M. & Ozcan, M. A. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 8, R52–R59 (2006).
pubmed: 16925824
pmcid: 1779467
doi: 10.1186/bcr1543
Zlatev, H. P., Auriola, S., Mönkkönen, J. & Määttä, J. A. Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells. Eur. J. Pharm. Sci. 86, 58–66 (2016).
pubmed: 26957415
doi: 10.1016/j.ejps.2016.02.016
Park, Y. E. et al. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells. Calcif. Tissue Int. 105, 497–505 (2019).
pubmed: 31324954
doi: 10.1007/s00223-019-00590-5
Waller, D. D., Park, J. & Tsantrizos, Y. S. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Crit. Rev. Biochem. Mol. Biol. 54, 41–60 (2019).
pubmed: 30773935
doi: 10.1080/10409238.2019.1568964
Elsayed, M. et al. Synergistic antiproliferative effects of zoledronic acid and fluvastatin on human pancreatic cancer cell lines: An in Vitro study. Biol. Pharm. Bull. 39, 1238–1246 (2016).
pubmed: 27181081
doi: 10.1248/bpb.b15-00746
Agabiti, S. S., Yilan, L. & Wiemer, A. J. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. Mol. Membr. Biol. 33, 1–11 (2016).
pubmed: 27537059
pmcid: 5532733
doi: 10.1080/09687688.2016.1213432
Waller, D. D., Park, J. & Tsantrizos, Y. S. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Crit. Rev. Biochem. Mol. Biol. 54, 41–60 (2019).
pubmed: 30773935
doi: 10.1080/10409238.2019.1568964
Park, J., Matralis, A. N., Berghuis, A. M. & Tsantrizos, Y. S. Human isoprenoid synthase enzymes as therapeutic targets. Front. Chem. 2, 1–21 (2014).
Räikkönen, J., Mönkkönen, H., Auriola, S. & Mönkkönen, J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem. Pharmacol. 79, 777–783 (2010).
pubmed: 19819230
doi: 10.1016/j.bcp.2009.10.003
Mohajeri, M., Behnam, B. & Sahebkar, A. Biomedical applications of carbon nanomaterials: Drug and gene delivery potentials. J. Cell. Physiol. 234, 298–319 (2018).
pubmed: 30078182
doi: 10.1002/jcp.26899
Schindeler, A. & Little, D. G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem. Biophys. Res. Commun. 338, 710–716 (2005).
pubmed: 16243296
doi: 10.1016/j.bbrc.2005.09.198
Recker, R. R. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 23, 6–16 (2008).
pubmed: 17892374
doi: 10.1359/jbmr.070906
Peter, B. et al. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 36, 52–60 (2005).
pubmed: 15664002
doi: 10.1016/j.bone.2004.10.004
Ebert, R. et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44, 858–864 (2009).
pubmed: 19442618
doi: 10.1016/j.bone.2009.01.009
Frandsen, C. J., Brammer, K. S. & Jin, S. Variations to the nanotube surface for bone regeneration. Int. J. Biomater. 2013, 1–10 (2013).
doi: 10.1155/2013/513680
Logan, N. & Brett, P. The control of mesenchymal stromal cell osteogenic differentiation through modified surfaces. Stem Cells Int. 2013, 1–10 (2013).
doi: 10.1155/2013/361637
Allan, C. et al. Osteoblast response to disordered nanotopography. J. Tissue Eng. 9, 1–7 (2018).
doi: 10.1177/2041731418784098
Boccaccini, A. R., Ege, D., Kamali, A. R. & Boccaccini, A. R. Graphene Oxide / Polymer-Based Biomaterials Graphene Oxide / Polymer-Based Biomaterials. Adv. Eng. Mater. 1700627, 16–34 (2017).
Carbonare, L. D. et al. Enhanced osteogenic differentiation in zoledronate-treated osteoporotic patients. Int. J. Mol. Sci. 18, 1–12 (2017).
Kolanthai, E. et al. Graphene Oxide - A Tool for the Preparation of Chemically Crosslinking Free Alginate-Chitosan-Collagen Scaffolds for Bone Tissue Engineering. ACS Appl. Mater. Interfaces 10, 12441–12452 (2018).
pubmed: 29589895
doi: 10.1021/acsami.8b00699
Ou, L. et al. Toxicity of graphene-family nanoparticles: A general review of the origins and mechanisms. Part. Fibre Toxicol. 13, 57–81 (2016).
pubmed: 27799056
pmcid: 5088662
doi: 10.1186/s12989-016-0168-y
Basso, F. G. et al. Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid. Braz. Oral Res. 30, e122 (2016).
pubmed: 27901204
doi: 10.1590/1807-3107bor-2016.vol30.0122
Pozzi, S. et al. High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties. Clin. Cancer Res. 15, 5829–5840 (2009).
pubmed: 19737962
doi: 10.1158/1078-0432.CCR-09-0426
Hu, L. et al. Pretreatment with Bisphosphonate Enhances Osteogenesis of Bone Marrow Mesenchymal Stem Cells. Stem Cells Dev. 26, 123–132 (2016).
pubmed: 27736364
doi: 10.1089/scd.2016.0173
Igarashi, K., Hirafuji, M., Adachi, H., Shinoda, H. & Mitani, H. Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot. Essent. Fat. Acids 56, 121–125 (1997).
doi: 10.1016/S0952-3278(97)90508-1
Pan, B. et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34, 112–123 (2004).
pubmed: 14751568
doi: 10.1016/j.bone.2003.08.013
Basso, F. G., Turrioni, A. P. S., Hebling, J. & De Souza Costa, C. A. Inhibition of osteoblast activity by zoledronic acid. J. Bras. Patol. e Med. Lab. 49, 368–371 (2013).
doi: 10.1590/S1676-24442013000500011
Vaisman, D. N., McCarthy, A. D. & Cortizo, A. M. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates. Biol. Trace Elem. Res. 104, 131–140 (2005).
pubmed: 15894813
doi: 10.1385/BTER:104:2:131
pmcid: 15894813
Gao, F., Liu, Y., Liu, M. & Zhu, L. Zoledronic acid regulates osteoblast differentiation via the mTORC1 signaling pathway. 11, 4585–4594 (2018).
Yang, X. et al. Effects of graphene oxide and graphene oxide quantum dots on the osteogenic differentiation of stem cells from human exfoliated deciduous teeth. Artif. Cells, Nanomedicine Biotechnol. 47, 822–832 (2019).
doi: 10.1080/21691401.2019.1576706
Kang, E. S. et al. Size-dependent effects of graphene oxide on the osteogenesis of human adipose-derived mesenchymal stem cells. Colloids Surfaces B Biointerfaces 169, 20–29 (2018).
pubmed: 29747027
doi: 10.1016/j.colsurfb.2018.04.053
Lee, W. C. et al. Origin of Enhanced Stem Cell Growth and Differentiation on Graphene and Graphene Oxide. ACS Nano 5, 7334–7341 (2011).
pubmed: 21793541
doi: 10.1021/nn202190c
Bagri, A. et al. Structural evolution during the reduction of chemically derived graphene oxide. Nat. Chem. 2, 581–587 (2010).
pubmed: 20571578
doi: 10.1038/nchem.686
Schech, A. J., Nemieboka, B. E. & Brodie, A. H. Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction. J. Steroid Biochem. Mol. Biol. 132, 195–202 (2012).
pubmed: 22659283
pmcid: 3463743
doi: 10.1016/j.jsbmb.2012.05.008
Talukdar, Y., Rashkow, J. T., Lalwani, G., Kanakia, S. & Sitharaman, B. The effects of graphene nanostructures on mesenchymal stem cells. Biomaterials 35, 4863–4877 (2014).
pubmed: 24674462
pmcid: 3995421
doi: 10.1016/j.biomaterials.2014.02.054
Rampersad, S. N. Multiple applications of alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors 12, 12347–12360 (2012).
pubmed: 23112716
doi: 10.3390/s120912347
Das Murtey, M. & Ramasamy, P. in Modern Electron Microscopy in Physical and Life Sciences (ed. Janecek, M.) 161–183 (InTechOpen, 2016).
Brennan, M. Á., Renaud, A., Gamblin, A., Arros, C. D. & Nedellec, S. 3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jet- sprayed or electrospun micro-fiber scaffolds 3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jet-sprayed or el. Biomed. Mater. 10, 1–13 (2015).
doi: 10.1088/1748-6041/10/4/045019